Avatar

Systolic Heart Failure: Autonomic Nervous System Considerations

By Thomas Deering 8 Videos
702 views
June 15, 2021
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
11:18
CVRx | Barostim

Barostim and the Window of Opportunity in Class II/III HFrEF Patient…

Feat. G. Panjrath, D. Yaranov, J. Lindenfeld, J. Thomas Heywood
17:33
CVRx | Barostim

Beyond BeAT-HF: Real World Experience with Barostim

Feat. G. Panjrath
11:37
ACC 2022 Conference Coverage

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

Feat. P. Heidenreich
11:25
ACC 2023 Conference Coverage

ACC 2023: SGLT2i Use - Dos and Don'ts

Feat. A. Armbruster
12:30
Houston Methodist Hospital

Amyloidosis Types and Pathophysiology

Feat. B. Trachtenberg
27:14
MUSC Cardiology

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

Feat. R. Mentz
13:07
Michelle Kittleson

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

09:52
AHA 2022 Conference Coverage

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

Feat. R. Mentz
18:26
CVRx | Barostim

HFA 2023: Unlocking the Potential of Baroreflex Activation in Heart …

Feat. F. Zannad, J. Lindenfeld, M. Fudim
31:46
ACC 2024 Insights

ACC 2024 Insights: Evolving Pharmacology for HFrEF vs. HFpFF - With …

Feat. M. Costanzo
16:32
CVRx | Barostim

ESC 2023: BeAT-HF: Long term outcome

Feat. M. Zile
09:58
CVRx | Barostim

Barostim for HFrEF Patients

Feat. P. Mccann
06:59
CVRx | Barostim

VAM 2023: Baroreflex Activation Therapy - A Novel Extravascular Proc…

Feat. C. Darling, M. PEREZ-IZQUIERDO
11:43
CVRx | Barostim

ESC 2023: Real-world experience with Baroreflex Activation Therapy

Feat. F. Arribas
16:00
CVRx | Barostim

HFA 2023: BeAT-HF: Long-Term Safety Profile and Outcomes

Feat. F. Zannad
07:52
CVRx | Barostim

VAM 2023: Baroreflex Activation Therapy - A Novel Extravascular Proc…

Feat. C. Darling
35:16
Scripps Health

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Feat. M. Kittleson
07:42
CVRx | Barostim

HFA 2023: Autonomic Dysfunction in HFrEF

Feat. M. Fudim
14:19
UChicago Medicine

S-QUAD Therapy and Beyond: HFpEF in 2024

Feat. M. Belkin
18:36
CVRx | Barostim

Barostim and the Window of Opportunity in Class II/III HFrEF Patient…

Feat. W. Abraham, G. Panjrath, D. Yaranov, P. Mccann